Senior Vice President OnKure Therapeutics Boulder, Colorado
Join Kevin Litwiler, Ph.D., Scientific Programming Chair, and several authors in Forum #2 in the Solution Center for a conversation about posters he is especially excited about.
M1530-04-24, A Brief Review of FDA-Approved New Drug Applications Labeled with Sprinkle Administration, Heather Boyce, Ph.D., US Food and Drug Administration
M0930-11-65, A Mechanistic PBPK Model for Maraviroc to Elucidate the Dose Related Non-Linearity in Oral Absorption using a Middle-Out Approach, Amin Rostami-Hodjegan, Pharm.D., Ph.D., University of Manchester
M0930-02-11, A Novel Fed State Approach to the Application of the Developability Classification System, Maria Ines Silva, Pharm.D., University of Strathclyde
T1530-11-62, Effect of Intestinal Precipitation on Cinnarizine Plasma Profile in Fasted State Employing Biorelevant In Vitro Tools and GastroPlus® Modeling, Siddharth Kesharwani, Ph.D., Sanofi
M1330-11-65, The Impact of Back Conversion of Acyl Glucuronide Metabolites on the Bioequivalence Studies Submitted in Abbreviated New Drug Applications, Jan-Shiang Taur, US Food and Drug Administration
M1130-04-24, The Impact of Cyclodextrin on Fasting and Fed Bioequivalence Studies in Solid Oral Immediate-Release Drug Products, Joseph Kotsybar, Pharm.D., US Food and Drug Administration
